ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Gilead and Tango expand cancer partnership

by Ryan Cross
August 21, 2020 | APPEARED IN VOLUME 98, ISSUE 32

 

Gilead Sciences has expanded its collaboration with the start-up Tango Therapeutics. Tango uses CRISPR gene editing to discover weaknesses in cancer cells and thereby identify new drug targets. Gilead began working with Tango in 2018. The firms are now expanding their partnership from 5 targets to 15. Gilead will pay Tango $125 million up front, make a $20 million equity investment, and pay up to $410 million for each of the potential 15 programs. Tango is also getting $30 million from private investors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment